Valeant Pharmaceuticals Intl Inc.: Is a Recovery Possible?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has to address a growing number of long-standing issues before it can be considered a viable investment option.

| More on:
The Motley Fool

In a little over one year, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has gone from being a core holding to virtually nothing.

Valeant was once the darling of the market. Surging on a series of drug company acquisitions, Valeant even surpassed the big banks by market cap at one point before commencing that epic fall that resulted in billions evaporating.

How did this happen?

Valeant’s business model was reliant on scooping up other drug companies using cheap loans and then raising prices on newly acquired drugs. Unfortunately, those cheap loans had to be repaid, and the price increases on those drugs were significant enough to attract the attention of lawmakers and regulatory bodies in the U.S.

Additionally, the uncovering of questionable practices with a pharmacy distributor and accounting errors added to Valeant’s woes, ultimately leading to a change in the top management of the company.

Valeant’s stock price, which, at one point during the summer of 2015, was trading well over $250 per share, plummeted to just $30 and has since continued to lose value, dropping to below $13 this month.

New Valeant, but the same (and more) issues persist

One of the main issues that CEO Joseph Papa is tasked with is addressing a US$30 billion mountain of debt. With no new deals on the horizon, and the old business model effectively dead, Valeant is pivoting to a less controversial business model that will provide revenues needed to keep the company afloat.

To combat that mammoth debt pile, Valeant has noted repeatedly that the company would be selling non-core assets to pay down debt. Papa stated last year that selling some of those assets could raise as much as $8 billion.

Earlier this year, Valeant sold some of those assets, but that only garnered $2.1 billion, falling far short of what the company needs. Selling assets is only a stop-gap solution, however, as any debt relief will be offset because the company will no longer receive revenues from the sold-off products. Therefore, the new business model and asset sales need to coordinate with each other.

To add to Valeant’s woes, Bill Ackman — who was one of the loudest proponents and investors in the company — sold his stake in the beleaguered company last month, acknowledging the loss of billions in the company. Ackman’s sell-off sparked Valeant’s stock to drop to new lows.

Can Valeant recover?

Valeant’s recovery hinges on three key points that the company and investors need to come to terms with.

First, as far as bad news weighing down a stock, Valeant’s epic drop is perhaps the most memorable in recent memory, and that’s the first thing that current investors need to come to terms with. Valeant will not surge back up to the levels we saw two years ago or even anywhere close. Forget $200 or even $80 per share.

Second, this is a new Valeant. This new Valeant is going to need a different business model than its former self, as the cheap loans and quick acquisitions are no longer going to be in the cards. Management has done well in setting up distribution agreements and endeavouring to right the ship, but it is a difficult task that will take time.

Finally, Valeant’s debt is massive, but so too are the assets the company has at its disposal. Selling assets and bringing to market new products will be key to Valeant maintaining a flow of revenue, while the business model is revamped. Valeant has several new drugs coming to market, and other existing drugs that continue to perform well, including Xifaxan, the often-touted gastrointestinal drug which remains Valeant’s top-selling product.

Now, there are far better investments on the market for investors, many of which can offer growth and income prospects for investors that far exceed what Valeant can offer.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Demetris Afxentiou has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »